Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease
Alfredo Berruti(University of Turin), Luigi Dogliotti(Aarhus University Hospital), Roberto Mario Scarpa(Università Campus Bio-Medico), Carlo Terrone(University of Turin), R. Tarabuzzi(Ospedale San Luigi Gonzaga), Enrico Bollito(Prostate Cancer UK), Alessandra Mosca(Higher Institute on Territorial Systems for Innovation), M. Torta(Prostate Cancer UK), Cecilia Maria Cracco(University of Turin), Lucianna Russo(Prostate Cancer UK), Alberto Angeli(University of Turin), Marco Tucci(Prostate Cancer UK)
Cited by 136
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer
|Journal of Clinical Oncology|2005|1.9k
The Clinical Research Office of the Endourological Society Percutaneous Nephrolithotomy Global Study: Indications, Complications, and Outcomes in 5803 Patients
|Journal of Endourology|2011|818
A Clinical Outcome-Based Prospective Study on Venous Thromboembolism After Cancer Surgery
|Annals of Surgery|2005|688